IMR Press / FBL / Volume 9 / Issue 1 / DOI: 10.2741/1303

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Antipyretic therapy
Show Less
1 The William Harvey Research Institute, St Bartholomew’s and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
Front. Biosci. (Landmark Ed) 2004, 9(1), 956–966; https://doi.org/10.2741/1303
Published: 1 January 2004
Abstract

Antipyresis can be achieved by physical methods such as cooling the body with tepid water or by pharmacological means such as the administration of antipyretic drugs. The nonsteroid anti-inflammatory drugs (NSAIDs) including aspirin, have been used to combat fever since the end of the 19th century and the analgesic antipyretics, from about the same time. Most of the antipyretic analgesics such as acetanilide and phenacetin are no longer used in therapy because of their toxicity. However, the metabolite of these two drugs, acetaminophen, became a highly popular antipyretic in the 1950s and is now the antipyretic of first choice in most developed countries. The disadvantages of administering NSAIDs is their gastrotoxicity manifested as irritation, ulcers and bleeding of the stomach mucosa. Acetaminophen also is toxic to the liver in doses only slightly above the therapeutic dose. Thus, selective COX-2 inhibitors, which do not damage the stomach and are free fom hepatotoxicity, may be the drugs of choice for reducing fever in the future.

Keywords
Pharmacology
Prostaglandins
Cyclooxygenases
Non-Steroidal Anti-Inflammatory Drugs
Antipyretic Analgesics
Selective COX-2 inhibitors
Review
Share
Back to top